Intravenous (i.v.) administration of autoantigen effectively induces Ag-specific tolerance against experimental autoimmune encephalomyelitis (EAE). We and others have shown enhanced EAE severity in mice lacking IL-12 or its receptor, strongly suggesting an immunoregulatory effect of IL-12 signaling. To examine the role of IL-12 responsiveness in autoantigen-induced tolerance in EAE, we administered autoantigen i.v. in two distinct treatment regimes to wildtype and IL-12Rβ2 −/− mice, immunized to develop EAE. Administration at the induction phase suppressed EAE in wildtype and IL-12Rβ2 −/− mice however the effect was somewhat less potent in the absence of IL-12Rβ2. Expression of pro-inflammatory cytokines such as IFN-γ, IL-17 and IL-2, was inhibited in wild-type tolerized mice but less so in IL-12Rβ2 −/− mice. I.v. antigen was also effective in suppressing disease in both genotypes when given during the clinical phase of disease with similar CNS inflammation, demyelination and peripheral inflammatory cytokine profiles observed in both genotypes. There was however a mild impact of a lack of IL-12 signaling on Treg induction during tolerance induction compared to WT mice in this treatment regime. These findings show that the enhanced severity of EAE that occurs in the absence of IL-12 signaling can be effectively overcome by i.v. autoantigen, indicating that this therapeutic effect is not primarily mediated by IL-12 and that i.v. tolerance could be a powerful approach in suppressing severe and aggressive MS.
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Introduction
Induction of intravenous (i.v.) tolerance with specific autoantigens has been accomplished by administration of antigen in a variety of tolerogenic forms, including soluble protein/peptide, and antigencoupled splenocytes (Kennedy et al., 1988; Santambrogio et al., 1995; Ferguson et al., 2003; Li et al., 2008) . A range of mechanisms is involved in the induction of i.v. tolerance, including selective suppression of antigen-specific Th1 cytokines and induction of regulatory cytokines (Benson et al., 2000; Smith and Miller, 2006; Ilarregui et al., 2009) ). We have shown that when soluble antigen is administered after clinical disease onset, clonal deletion of antigen-reactive T cells by apoptosis is a major mechanism for the reversal of EAE (Zhang et al., 1999) . In contrast, when soluble antigen is administered before or immediately after immunization for EAE induction, an antigen-specific regulatory mechanism, but not deletion, prevails and appears to be the main mechanism for tolerance induction (Hilliard et al., 2000) .
IL-12 is a heterodimeric cytokine composed of a heavy chain (p40) and a light chain (p35). Heterodimeric IL-12 is produced mainly by activated APCs and has been shown to play an important role in the differentiation and expansion of Th1 cells (Trinchieri, 1998; Mullen et al., 2001 ). IL-12 exerts its effects through a receptor (IL-12R) composed of two chains, IL-12Rβ1 and IL-12Rβ2 (Gately et al., 1998) . In the mouse, IL-12Rβ1 mediates both low and high affinity binding to IL-12, whereas IL-12Rβ2 is thought to mediate transmembrane signaling, with negligible effects on binding (Gately et al., 1998) . Gene targeting studies suggest that the absence of either IL-12Rβ1 or IL-12Rβ2 impairs functional responses to IL-12 (1997 IL-12 ( , 2000 . The p40 subunit of IL-12 is also shared by IL-23, also a heterodimeric cytokine (p40 and p19 subunits) which has a strong effect in promoting the function and survival of Th17 cells (Langrish et al., 2005) . The receptor for IL-23 is a heterodimer composed of IL-12Rβ1 and IL-23R (Parham et al., 2002) . IL-12Rβ2 is required for biological response of IL-12 but not IL-23. Thus, the IL-12Rβ2-deficient model is a valuable tool to differentiate the role of these closely related cytokines and to specifically investigate a role for IL-12 signaling in the induction of tolerance. The 
